210 related articles for article (PubMed ID: 12183667)
1. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.
Maillard MP; Perregaux C; Centeno C; Stangier J; Wienen W; Brunner HR; Burnier M
J Pharmacol Exp Ther; 2002 Sep; 302(3):1089-95. PubMed ID: 12183667
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.
Wienen W; Hauel N; Van Meel JC; Narr B; Ries U; Entzeroth M
Br J Pharmacol; 1993 Sep; 110(1):245-52. PubMed ID: 8220885
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens; 2001 Mar; 19(3):465-73. PubMed ID: 11288817
[TBL] [Abstract][Full Text] [Related]
4. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
J Cardiovasc Pharmacol; 2001 Jul; 38(1):141-8. PubMed ID: 11444497
[TBL] [Abstract][Full Text] [Related]
5. Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta.
Nap A; Balt JC; Pfaffendorf M; Van Zwieten PA
J Hypertens; 2002 Sep; 20(9):1821-8. PubMed ID: 12195125
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
Belz GG; Butzer R; Kober S; Mutschler E
J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
9. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats.
Gohlke P; Weiss S; Jansen A; Wienen W; Stangier J; Rascher W; Culman J; Unger T
J Pharmacol Exp Ther; 2001 Jul; 298(1):62-70. PubMed ID: 11408526
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the effects of candesartan on responses to angiotensin II in the hindquarters vascular bed of the cat.
Champion HC; Bivalacqua TJ; Lambert DG; McNamara DB; Kadowitz PJ
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S101-3. PubMed ID: 9892149
[TBL] [Abstract][Full Text] [Related]
11. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
Inada Y; Naka T
Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
13. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor.
Ojima M; Inada Y; Shibouta Y; Wada T; Sanada T; Kubo K; Nishikawa K
Eur J Pharmacol; 1997 Jan; 319(1):137-46. PubMed ID: 9030909
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?
Vanderheyden PM; Fierens FL; Vauquelin G
Biochem Pharmacol; 2000 Dec; 60(11):1557-63. PubMed ID: 11077037
[TBL] [Abstract][Full Text] [Related]
15. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
Vanderheyden PM; Fierens FL; De Backer JP; Fraeyman N; Vauquelin G
Br J Pharmacol; 1999 Feb; 126(4):1057-65. PubMed ID: 10193788
[TBL] [Abstract][Full Text] [Related]
16. Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically-instrumented transgenic rats.
van Meel JC; Redemann N; Haigh RM
Arzneimittelforschung; 1996 Aug; 46(8):755-9. PubMed ID: 9125273
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.
Le MT; Pugsley MK; Vauquelin G; Van Liefde I
Br J Pharmacol; 2007 Aug; 151(7):952-62. PubMed ID: 17572702
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Montón M; Jiménez A; Núñez A; López-Blaya A; Farré J; Gómez J; Zalba LR; Sánchez de Miguel L; Casado S; López-Farré A
J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
[TBL] [Abstract][Full Text] [Related]
19. Effect of angiotensin II and telmisartan, an angiotensin1 receptor antagonist, on rat gastric mucosal blood flow.
Heinemann A; Sattler V; Jocic M; Wienen W; Holzer P
Aliment Pharmacol Ther; 1999 Mar; 13(3):347-55. PubMed ID: 10102968
[TBL] [Abstract][Full Text] [Related]
20. Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts.
Wang QD; Sjöquist PO
Eur J Pharmacol; 1999 Sep; 380(1):13-21. PubMed ID: 10513555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
